Healthcare provider profile · identity verified

Alicia Bordon, MD

Internal Medicine · HOUSTON, TX · NPI 1629280177

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	248	90
Losartan Potassium	Losartan Potassium	228	78
Amlodipine Besylate	Amlodipine Besylate	225	71
Metformin Hcl	Metformin Hcl	204	73
Lisinopril	Lisinopril	187	61
Levothyroxine Sodium	Levothyroxine Sodium	163	48
Simvastatin	Simvastatin	160	56
Omeprazole	Omeprazole	136	48
Meloxicam	Meloxicam	122	29
Gabapentin	Gabapentin	108	40
Montelukast Sodium	Montelukast Sodium	106	33
Escitalopram Oxalate	Escitalopram Oxalate	100	31
Vitamin D2	Ergocalciferol (Vitamin D2)	97	44
Azithromycin	Azithromycin	89	70
Tamsulosin Hcl	Tamsulosin Hcl	88	28
Alendronate Sodium	Alendronate Sodium	87	33
Fenofibrate	Fenofibrate Nanocrystallized	75	29
Zolpidem Tartrate	Zolpidem Tartrate	68	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	61	49
Ozempic	Semaglutide	61	11
Ibuprofen	Ibuprofen	56	21
Valsartan	Valsartan	56	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	53	40
Hydralazine Hcl	Hydralazine Hcl	52	16
Diclofenac Sodium	Diclofenac Sodium	50	29
Hydrochlorothiazide	Hydrochlorothiazide	49	16
Pantoprazole Sodium	Pantoprazole Sodium	49	16
Nifedipine Er	Nifedipine	48	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	45	18
Tramadol Hcl	Tramadol Hcl	45	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	13
Clonidine Hcl	Clonidine Hcl	42	18
Metoprolol Succinate	Metoprolol Succinate	41	16
Metoprolol Tartrate	Metoprolol Tartrate	41	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	33
Ofloxacin	Ofloxacin	39	33
Albuterol Sulfate Hfa	Albuterol Sulfate	38	19
Glipizide	Glipizide	37	13
Trazodone Hcl	Trazodone Hcl	36	suppressed
Alprazolam	Alprazolam	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	13
Glimepiride	Glimepiride	33	11
Clopidogrel	Clopidogrel Bisulfate	31	11
Ezetimibe	Ezetimibe	31	13
Prednisone	Prednisone	30	21
Sildenafil Citrate	Sildenafil Citrate	29	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	28	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	11
Memantine Hcl	Memantine Hcl	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	15
Pravastatin Sodium	Pravastatin Sodium	23	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Clonazepam	Clonazepam	22	suppressed
Gemfibrozil	Gemfibrozil	22	suppressed
Sertraline Hcl	Sertraline Hcl	22	suppressed
Famotidine	Famotidine	21	suppressed
Ondansetron Odt	Ondansetron	21	suppressed
Clotrimazole	Clotrimazole	20	14
Finasteride	Finasteride	20	suppressed
Meclizine Hcl	Meclizine Hcl	20	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	20	suppressed
Furosemide	Furosemide	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Methylprednisolone	Methylprednisolone	17	16
Carvedilol	Carvedilol	16	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Linzess	Linaclotide	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Sucralfate	Sucralfate	14	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Megestrol Acetate	Megestrol Acetate	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error